期刊
TRENDS IN CANCER
卷 4, 期 2, 页码 119-137出版社
CELL PRESS
DOI: 10.1016/j.trecan.2017.12.007
关键词
-
类别
资金
- National Institutes of Health [RO1CA201189, R01CA180913, R01AI081848]
- Cancer Research Institute
- Melanoma Research Alliance
- Icahn School of Medicine at Mount Sinai, NY, Cancer Immunotherapy Program
- NATIONAL CANCER INSTITUTE [R01CA180913, R01CA201189] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007605, R01AI081848] Funding Source: NIH RePORTER
Dendritic cells (DCs) are essential in immunity owing to their role in activating T cells, thereby promoting antitumor responses. Tumor cells, however, hijack the immune system, causing T cell exhaustion and DC dysfunction. Tumor-induced T cell exhaustion may be reversed through immune checkpoint blockade (ICB); however, this treatment fails to show clinical benefit in many patients. While ICB serves to reverse T cell exhaustion, DCs are still necessary to prime, activate, and direct the T cells to target tumor cells. In this review we provide a brief overview of DC function, describe mechanisms by which DC functions are disrupted by the tumor microenvironment, and highlight recent developments in DC cancer vaccines.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据